Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Limits of Resistance and Future Directions
John cautions on other resistance mechanisms (e.g., PLCG2) and anticipates studies in CLL and broader settings.
Play episode from 16:18
Transcript
